Osteoporosis drug set to cut hip surgery need
This article was originally published in Clinica
Executive Summary
The adoption of a novel drug regimen that is expected to be approved by the end of next year would almost halve the incidence of osteoporosis-related hip fractures, with significant implications for the hip replacement market.